Adam Feuerstein

Adam Feuerstein Recent News

Alkermes Falls 20% After FDA Refusal To File Letter
Omeros Spikes 37% Amid Favorable Medicare Policy In Congressional Spending Bill
Proteostasis Tumbles 25% After Short Seller Calls Leading Drug Candidate 'A Dud'
Novavax Shares Rise 30% On Positive Data, But Risks Remain
Pain Therapeutics Shares Double On Clinical Study Data
10 Financial Twitter Names To Follow In 2018
'Horrible': JPMorgan Chase Receives Pushback On Biotech Conference Restrictions
4 Biotechs Boosted By Spark Therapeutic's FDA News
A Deep Dive Into MannKind's Big Bet On Afrezza
Selling The News In Acadia Pharmaceuticals
Acadia's FDA Breakthrough Designation For Pimavanserin Draws Mixed Response
Zogenix's Dravet Syndrome Treatment Returns 'Strong'
Anlayst: NewLink Shares Have Doubled This Month And There's Still Room For More Upside
Street Puts Stamp Of Approval On Gilead's Kite Pharma Takeover
Puma Biotech Makes Big Breakthrough In Breast Cancer Treatment
Will TherapeuticsMD's Yuvvexy Pass The FDA Muster?
'Riding So More Jimmy's Can Ring The Bell': TheStreet's Adam Feuerstein To Bike For Jimmy Fund, Dana-Farber Cancer Institute
Neurotrope Denies Involvement In Paying For Promotional Articles
PreMarket Prep Recap For May 1: Feuerstein Breaks Down Neurotrop's Data Spin; Contrarianism Vs. Momentum Investing
Feuerstein On Neurotrope: The Study Failed And There Was Never 'A Lot Of Hope Here'
Neurotrope's Phase 2 Drug To Treat Alzheimer's Doesn't Clear Threshold For Statistical Significance
Exondys Sales, Takeover Speculation Fuel Sarepta Therapeutics
The Bull-Bear Debate In Therapeutics Rages From Research Notes To Twitter